Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
Authors
Keywords
CML, BCR-ABL1, Therapeutic strategies, Immunological approaches
Journal
Molecular Cancer
Volume 17, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-02-15
DOI
10.1186/s12943-018-0805-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
- (2017) C Schütz et al. LEUKEMIA
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- The HSP90 chaperone machinery
- (2017) Florian H. Schopf et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- New tricks for human farnesyltransferase inhibitor: cancer and beyond
- (2017) Jingyuan Wang et al. MedChemComm
- The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia
- (2017) Muhammad Rauzan et al. PLoS One
- Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia
- (2016) Elena Ceccacci et al. BRITISH JOURNAL OF CANCER
- Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells
- (2016) Yasufumi Matsuda et al. CANCER SCIENCE
- Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes
- (2016) Fabio Stagno et al. Expert Review of Anticancer Therapy
- Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells
- (2016) WEI HE et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Targeting the mTOR Pathway in Leukemia
- (2016) Shira Dinner et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
- (2016) Jeffrey H Lipton et al. LANCET ONCOLOGY
- A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
- (2016) M Wagle et al. LEUKEMIA
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
- (2016) A Hochhaus et al. LEUKEMIA
- The concept of treatment-free remission in chronic myeloid leukemia
- (2016) S Saußele et al. LEUKEMIA
- Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
- (2016) Gianantonio Rosti et al. Nature Reviews Clinical Oncology
- Protein prenylation: unique fats make their mark on biology
- (2016) Mei Wang et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia
- (2016) David A. Irvine et al. Scientific Reports
- A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
- (2015) G. Borthakur et al. HAEMATOLOGICA
- A novel compound against oncogenic Aurora kinase A overcomes imatinib resistance in chronic myeloid leukemia cells
- (2015) ZI-JIE LONG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- GLI2 inhibition abrogates human leukemia stem cell dormancy
- (2015) Anil Sadarangani et al. Journal of Translational Medicine
- Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells
- (2015) C Riether et al. LEUKEMIA
- A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
- (2015) G. Borthakur et al. HAEMATOLOGICA
- Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study
- (2015) Giovanni Martinelli et al. Lancet Haematology
- Aurora Kinase Inhibitors: Current Status and Outlook
- (2015) Vassilios Bavetsias et al. Frontiers in Oncology
- Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
- (2014) Carlo Gambacorti-Passerini et al. AMERICAN JOURNAL OF HEMATOLOGY
- JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
- (2014) P. Gallipoli et al. BLOOD
- IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation
- (2014) Michele Massimino et al. CARCINOGENESIS
- Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia
- (2014) V. Gandhi et al. CLINICAL CANCER RESEARCH
- Sirtuin inhibitors as anticancer agents
- (2014) Jing Hu et al. Future Medicinal Chemistry
- Do we need more drugs for chronic myeloid leukemia?
- (2014) Tessa L. Holyoake et al. IMMUNOLOGICAL REVIEWS
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting RAS–ERK signalling in cancer: promises and challenges
- (2014) Ahmed A. Samatar et al. NATURE REVIEWS DRUG DISCOVERY
- A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
- (2014) J F Seymour et al. Blood Cancer Journal
- Immunology and Immunotherapy of Chronic Myeloid Leukemia
- (2014) Mette Ilander et al. Current Hematologic Malignancy Reports
- Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
- (2013) J. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation
- (2013) Seiichi Okabe et al. CANCER BIOLOGY & THERAPY
- Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
- (2013) Seiichi Okabe et al. Cancer Cell International
- A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition
- (2013) Daniel J. Goff et al. Cell Stem Cell
- Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib
- (2013) Jorge E. Cortes et al. Clinical Lymphoma Myeloma & Leukemia
- Roles of SIRT1 in leukemogenesis
- (2013) WenYong Chen et al. CURRENT OPINION IN HEMATOLOGY
- BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein
- (2013) Pietro Buffa et al. FASEB JOURNAL
- PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
- (2013) Paolo Neviani et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex
- (2013) Min Chen et al. JNCI-Journal of the National Cancer Institute
- Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia
- (2013) Concetta Quintarelli et al. LEUKEMIA RESEARCH
- Suppression of Survivin Induced by a BCR-ABL/JAK2/STAT3 Pathway Sensitizes Imatinib-Resistant CML Cells to Different Cytotoxic Drugs
- (2013) S. Stella et al. MOLECULAR CANCER THERAPEUTICS
- Correction: Characterization of PUD-1 and PUD-2, Two Proteins Up-Regulated in a Long-Lived daf-2 Mutant
- (2013) Yue-He Ding et al. PLoS One
- Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia
- (2013) Susanne Badura et al. PLoS One
- PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor
- (2013) K Airiau et al. Cell Death & Disease
- Signal Transduction in the Chronic Leukemias: Implications for Targeted Therapies
- (2013) Wesam Ahmed et al. Current Hematologic Malignancy Reports
- Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
- (2012) J. Cortes et al. BLOOD
- Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib
- (2012) Ling Li et al. CANCER CELL
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Danusertib, an aurora kinase inhibitor
- (2012) Hielke J Meulenbeld et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia
- (2012) F J Giles et al. LEUKEMIA
- Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1
- (2012) A R Soliera et al. LEUKEMIA
- Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor
- (2012) Manuela Mancini et al. LEUKEMIA RESEARCH
- SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells
- (2012) Z Wang et al. ONCOGENE
- Interferon and PV stem cells
- (2011) J. T. Prchal BLOOD
- Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis
- (2011) H. Yuan et al. BLOOD
- Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
- (2011) A. Hamilton et al. BLOOD
- Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia
- (2011) Jorge Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of the hedgehog pathway in chronic myelogeneous leukemia patients
- (2011) Bing Long et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors
- (2011) E Traer et al. LEUKEMIA
- Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells
- (2011) E K Allan et al. LEUKEMIA
- Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
- (2011) W. Ying et al. MOLECULAR CANCER THERAPEUTICS
- The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells
- (2011) Y Kuwatsuka et al. Blood Cancer Journal
- Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells
- (2010) R. Tanaka et al. BLOOD
- K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate
- (2010) B. D. Smith et al. CLINICAL CANCER RESEARCH
- WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient
- (2010) Yusuke Oji et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
- (2010) Kevin R. Kelly et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
- (2010) Amie S. Corbin et al. JOURNAL OF CLINICAL INVESTIGATION
- Critical molecular pathways in cancer stem cells of chronic myeloid leukemia
- (2010) Y Chen et al. LEUKEMIA
- Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination
- (2010) Monica Bocchia et al. Nature Reviews Clinical Oncology
- Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
- (2009) S. Mumprecht et al. BLOOD
- Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies
- (2009) David T. Teachey et al. BRITISH JOURNAL OF HAEMATOLOGY
- Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease
- (2009) Nitin Jain et al. CANCER
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
- (2009) Peter Atadja CANCER LETTERS
- mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein
- (2009) Manuela Mancini et al. LEUKEMIA RESEARCH
- Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
- (2009) Chen Zhao et al. NATURE
- Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I
- (2008) A. Gontarewicz et al. BLOOD
- Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation
- (2008) Christine Dierks et al. CANCER CELL
- Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis
- (2008) Hugues de Lavallade et al. JOURNAL OF CLINICAL ONCOLOGY
- Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase
- (2008) Ji Wu et al. JNCI-Journal of the National Cancer Institute
- Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin
- (2008) L X Wu et al. LEUKEMIA
- Novel Agents in CML Therapy: Tyrosine Kinase Inhibitors and Beyond
- (2008) J. V. Melo et al. Hematology-American Society of Hematology Education Program
- Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis
- (2007) Fabio Stagno et al. LEUKEMIA RESEARCH
- The BCL-2 protein family: opposing activities that mediate cell death
- (2007) Richard J. Youle et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started